Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States.
Interv Neuroradiol. 2022 Apr;28(2):145-151. doi: 10.1177/15910199211019175. Epub 2021 May 26.
Jugular paragangliomas represent a surgical challenge due to their vascularity and proximity to vital neurovascular structures. Preoperative embolization aids in reducing intraoperative blood loss, transfusion requirements, and improves surgical visualization. Several embolization agents have been used.
The aim of this study is to evaluate the safety and efficacy of PVA in pre-operative embolization of jugular paragangliomas.
A retrospective review of all patients who underwent jugular paraganglioma resection with pre-operative embolization between 2000 and 2020 was performed. Pre-operative data including baseline patient and tumor characteristics were documented. Outcomes of preoperative embolization including extent of devascularization and post-embolization complications were recorded. Early and long-term postoperative outcomes were reported.
Twenty-nine patients met study criteria with a median age of 38 years. Average tumor size was 3.4±1.8 cm. The most commonly encountered arterial feeder was the ascending pharyngeal artery followed by the posterior auricular artery. More than 50% reduction in tumor blush was achieved in 25 patients (86.2%). None of the patients experienced new or worsening cranial neuropathy following embolization. Gross total or Near total resection was achieved in 13 patients (44.8%). A STR or NTR was chosen in these patients to preserve cranial nerve function or large vessel integrity. Average intraoperative estimated blood loss was 888 ml, 9 patients (31%) required intra-operative transfusion of blood products. Extent of resection and post-operative complications did not correlate with extent of devascularization.
Pre-operative embolization of jugular paraganglioma tumors with PVA particles is an effective strategy with a high safety profile.
颈静脉球副神经节瘤因其血管丰富且靠近重要的神经血管结构而具有手术挑战性。术前栓塞有助于减少术中失血量、输血需求,并改善手术可视化。已经使用了几种栓塞剂。
本研究旨在评估 PVA 在颈静脉球副神经节瘤术前栓塞中的安全性和有效性。
回顾性分析了 2000 年至 2020 年间接受颈静脉球副神经节瘤切除术并进行术前栓塞的所有患者。记录了术前数据,包括基线患者和肿瘤特征。记录了术前栓塞的结果,包括血管阻断程度和栓塞后并发症。报告了早期和长期的术后结果。
29 例患者符合研究标准,平均年龄为 38 岁。平均肿瘤大小为 3.4±1.8cm。最常见的动脉供血动脉是咽升动脉,其次是耳后动脉。25 例患者(86.2%)肿瘤血供减少 50%以上。栓塞后无患者出现新的或恶化的颅神经病变。13 例患者(44.8%)实现了大体全切除或近全切除。为了保留颅神经功能或大血管完整性,这些患者选择了 STR 或 NTR。术中估计失血量平均为 888ml,9 例(31%)患者需要术中输血。切除程度和术后并发症与血管阻断程度无关。
用 PVA 颗粒对颈静脉球副神经节瘤进行术前栓塞是一种有效且安全性高的策略。